a School of Medicine , University of Belgrade , Belgrade , Serbia.
b Department for Colorectal and Pelvic Surgery , First Surgical Clinic, Clinical Center of Serbia , Belgrade , Serbia.
Int J Hyperthermia. 2018 Aug;34(5):564-569. doi: 10.1080/02656736.2017.1371341. Epub 2017 Sep 7.
With standard treatment of epithelial ovarian cancer (EOC), prognosis is very poor. The aim of this study is to show early and late results in patients who underwent cytoreductive surgery and intraperitoneal chemotherapy.
This was a retrospective single centre study. All patients with advanced and recurrent ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) or modified early postoperative intraperitoneal chemotherapy (EPIC) were included in the study.
In the period 1995-2014, 116 patients were treated, 55 with primary EOC and 61 with recurrent EOC. The mean age was 59 years (26-74). Statistically, median survival time was significantly longer in the group with primary advanced cancer of the ovary (41.3 months) compared to relapsed ovarian cancer (27.3 months). Survival for the primary EOC was 65 and 24% at 3 and 5 years, respectively. Survival for recurrent EOC was 33 and 16% at 3 and 5 years, respectively. Mortality was 1/116 (0.8%). Morbidity was 11/116 (9.5%). Peritoneal cancer index (PCI) was ≤20 in 59 (51%) patients and statistically, their average survival was significantly longer than in the group of 57 (49%) patients with PCI >20 (p = 0.014).
In advanced or recurrent EOC, a curative therapeutic approach was pursued that combined optimal cytoreductive surgery and intraperitoneal chemotherapy. PCI and timing of the intervention (primary or recurrent) were the strongest independent prognostic factors.
上皮性卵巢癌（EOC）采用标准治疗，预后极差。本研究旨在展示接受细胞减灭术和腹腔内化疗的患者的早期和晚期结果。
这是一项回顾性单中心研究。所有接受细胞减灭术和腹腔内热化疗（HIPEC）或改良早期术后腹腔内化疗（EPIC）治疗的晚期和复发性卵巢癌患者均纳入本研究。
1995 年至 2014 年期间，共治疗了 116 例患者，其中 55 例为原发性卵巢 EOC，61 例为复发性卵巢 EOC。平均年龄为 59 岁（26-74 岁）。统计上，原发性晚期卵巢癌组的中位生存时间（41.3 个月）明显长于复发性卵巢癌组（27.3 个月）。原发性 EOC 的 3 年和 5 年生存率分别为 65%和 24%。复发性 EOC 的 3 年和 5 年生存率分别为 33%和 16%。死亡率为 1/116（0.8%）。发病率为 11/116（9.5%）。腹膜癌指数（PCI）≤20 的患者有 59 例（51%），统计上，他们的平均生存时间明显长于 PCI>20 的 57 例患者（p=0.014）。
在晚期或复发性 EOC 中，采用了结合最佳细胞减灭术和腹腔内化疗的治愈性治疗方法。PCI 和干预时机（原发性或复发性）是最强的独立预后因素。
